GNMX | tickerfilter.com

Fundamental analysis

25%

Profitability 32%

Dept financing 35%

Liquidity 16%

Performance 17%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

0 0%

1 Month

0 0%

3 Months

0 0%

6 Months

0 0%

1 Year

0 0%

2 Year

0 0%

Key data

Stock price

$0.17

P/E Ratio

N/A

DAY RANGE

$0.17 - $0.17

EPS

-$0.30

52 WEEK RANGE

$0.11 - $0.35

52 WEEK CHANGE

-$27.78

MARKET CAP

12.893 M

YIELD

N/A

SHARES OUTSTANDING

77.714 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

N/A

BETA

0.00

PUBLIC FLOAT

$41,437,023

AVERAGE 10 VOLUME

$2,636,384

AVERAGE 30 VOLUME

$2,547,379

Company detail

CEO:
Region: US
Website: http://www.aevigenomics.com
Employees: 14
IPO year: -

Issue type: Common Stock
Market: NASDAQ
Industry: Biotechnology
Sector: Health Technology

Aevi Genomic Medicine, Inc. is a clinical stage biopharmaceutical company, which engages in finding treatments for rare and orphan diseases. Its research and development efforts leverage an internal genomics platform and an ongoing collaboration with the Center for Applied Genomics (CAG) at The Children's Hospital of Philadelphia (CHOP). The company was founded by Andrew Leonard Pearlman on January 27, 2000 and is headquartered in Wayne, PA.

GNMX - Aevi Genomic Medicine Inc.